Category Archives: Biotech

Managing High Priced, U.S. Biotech Rxs in Canada

As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are […]
Also posted in Global, Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment

Catching Biopharmaceutical Sponsors by Surprise

The FDA has always been concerned about the safety of patients, and they strongly believe that clinical trials are not sufficient to capture all drug related adverse effects. During an update on The Future of FDA’s Drug Safety Program, Andrew C. von Eschenbach stated, “The full magnitude of some potential risks does not always emerge […]
Also posted in FDA, Regulatory, Safety | Tagged | Leave a comment

Biotech Stocks Shaken by Fed Warning

Today’s Financial Times (FT) reports that nearly $40bn was wiped from the biotech market’s value last week (a 6 per cent drop in the Nasdaq biotechnology index) following the Federal Reserve’s identification of biotech shares as a cause for concern. There was some recovery on Friday however when prices rebounded 3 per cent. The US […]
Posted in Biotech | Tagged , , | Leave a comment

The Technologies Set to Transform Healthcare

By G. Steven Burrill, CEO, Burrill & Company. The promise of precision medicine is beginning to bear fruit as deadly diseases are made treatable, doctors use genetic information to guide treatment decisions, and the convergence of information, communications, and biological technology reinvents the practice of medicine. The arrival of this new age of medicine has […]
Also posted in Global, Guest Blog, healthcare, Op-Ed, Technology | Tagged , , , | Leave a comment

Strong IP Plans Essential for UK Life Sciences Clusters

By John Dean, Withers & Rogers LLP. Life sciences and biotech research clusters across the UK, including those linked to university research departments are benefiting from an improved funding climate and ongoing consolidation in the pharmaceutical sector. However, as big pharma companies increasingly vie for the best spin-out investment opportunities, those with strategic intellectual property […]
Also posted in Europe, Global, Guest Blog, IP, Strategy | Tagged , , , | Leave a comment
  • Categories

  • Meta